Defines Capital Blue Cross medical policy MP 2.303 on the use of medications administered under heavy sedation or general anesthesia for opioid use disorder (ultra-rapid/anesthesia-assisted withdrawal). Policy subject: Medications used under heavy sedation or general anesthesia for opioid use disorder (ultra-rapid withdrawal management). Status: RETIRED with retirement effective date RETIRED 6/1/2025.

The evidence is limited and insufficient to conclude benefit: available data include randomized and nonrandomized clinical trials and prospective follow-up studies but are sparse and lack a standardized approach to ultra-rapid withdrawal management.

Safety concerns and reported serious, including life‑threatening, adverse events have been documented, and most patients in follow-up studies subsequently return to daily opioid use, resulting in high relapse rates; these factors support the investigational/non‑covered determination.

Coding note: Providers should verify coding based on the actual services provided and payer billing rules. Benefit determination must follow the member's health benefit plan language and preauthorization requirements, as medical policy does not guarantee coverage.

Ultra-rapid (also called anesthesia-assisted or one-day) opioid withdrawal uses relatively high doses of opioid antagonist medications under deep sedation or general anesthesia to accelerate the acute phase of withdrawal, typically completed within 24–48 hours. The approach is used with ongoing medication for opioid use disorder and psychosocial support.

Programs typically include three phases: a comprehensive evaluation, inpatient withdrawal management under anesthesia (or heavy sedation), and mandatory post‑withdrawal care and follow-up. When general anesthesia is used, hospital admission is required; some heavy sedation programs may be outpatient.

Evidence summary: Insufficient and limited. The literature includes randomized and nonrandomized trials and follow-up studies but shows a paucity of controlled data, lack of a standardized technique, safety concerns including severe adverse events, and high rates of relapse to daily opioid use.

Reference to CMS Medicare Policy 130-7 is noted in the policy (CMS Medicare Policy 130-7). No effective date or policy number is provided in this document; consult CMS Medicare Policy 130-7 directly for details.